Objective: To evaluate the efficiency and safety of "TINMAX" HB-3 Herbal Compound (cpd) in treatment of hepatofibrosis and cirrhosis post chronic hepatitis B. Methods: A double-blind randomized method was employed. 60 patients of hepatofibrosis or cirrhosis post hepatitis B were separated into study group ("TINMAX" HB-3 group) and control group (natural vitamin group) by randomized method. The course was 52 weeks. Patients visited once every 12 weeks and the last visit at 12 weeks after the cessation of treatment. Part of patients had liver biopsy before and after treatment. Before, during the course and at the end of therapy, clinical symptoms and physical signs were evaluated, hepatic function, and serum markers of hepatofibrosis (such as hyaluronate acid, laminin, serum type III procollagen and collagen IV) were tested, and ultrasound evaluation was performed. Results: 60 patients enrolled in the evaluation. 58 patients completed the evaluation according to the protocol. 20 patients had liver biopsy twice, 10 from the study group and 10 from the other one. At the end of therapy, the total effective rate of hepatofibrosis in histopathology is 74.13% in the study group, much higher than that of 21.95% in the control group (P<0.05). The total effective rate of serum markers of hepatofibrosis at the end of therapy in the study group was 70.10%, much higher than that of 30.24% in the control group (P<0.05). The total effective rate of non-invasion markers of hepatofibrosis at the end of therapy in the study group was 76.08%, much higher than that of 19.41% in the control group (P<0.05). The drugs of adverse event had not happened in both groups. Conclusion: "TINMAX" HB-3 herbal compound (cpd) is effective and safe in treatment of hepatofibrosis and cirrhosis post chronic hepatitis B.